The company has also appointed Elisha Orr, a cancer researcher and the developer of the company’s antibody technology, as the director and chief scientific officer of the Belgian subsidiary.
The Belgian subsidiary was established in order to accelerate the development and commercialization of MabCure’s proprietary products for the early detection of cancer with specific antibodies and for the creation of highly specific therapeutics (antibodies and novel drugs) against cancer. MabCure NV will be eligible to apply for research grants from the Flemish government.
The Belgian subsidiary will be located on the Biomed campus of the University of Hasselt. In addition to its own R&D program, MabCure NV plans to develop joint projects with the University of Hasselt, deploying MabCure’s technology. MabCure’s global headquarters will be relocated to Hasselt, Belgium as well.